IPD Group (ASX: IPG) Reports Impressive H1 FY 2025 Results: But Are There Gremlins Under The Surface?
IPD Group (ASX: IPG) reported decent results and the IPD Group share price has moved up slightly, despite weak commercial construction.
Company Coverage
XRF Scientific (ASX: XRF) Share Price Gains On Solid H1 FY 2025 Results
Solid results from a company that just keeps on delivering growth.
Netwealth (ASX: NWL) Posts Record Inflows, But Can It Maintain the Momentum?
Netwealth (ASX: NWL) posts record inflows, hitting $101.6B FUA. Can it sustain momentum as legacy platforms decline?
An Introduction To Pharmx (ASX:PHX) After Its H1 FY 2025 Results
I will be keeping an eye on the PharmX (ASX: PHX) share price because the PharmX business model seems to have the potential to scale nicely.
Audinate (ASX: AD8) H1 FY 2025 Results: Has The Worst Passed?
Growth Gauge has long followed Audinate shares, and is expecting more optimism in the future, after the undeniably tough H1 FY 2025 results were released.
BSA Ltd (ASX:BSA) Director Sold Shares Before 80% BSA Share Price Fall
The BSA Ltd share price fell 83% yesterday.
HUB24 (ASX: HUB) Share Price Gains On Record H1 FY 2025 Results
It’s easy to tell the H1 FY 2024 Hub24 (ASX: HUB) results were good. But I’m less confident that there is still value on offer after the stock has doubled in price.
An Introduction To Centrepoint Alliance (ASX: CAF)
Chris Coe explains why he recently bought some share in this little known dividend stock with a P/E ratio around 9.
Fiducian Group (ASX: FID) Reports Solid H1 FY 2025 Results
The Fiducian Group share price gained around 10% in response to some fairly solid H1 FY 2025 results.
Adore Beauty (ASX: ABY) Expands Retail Footprint, But Will It Boost Sales?
Adore Beauty (ASX: ABY) reports strong margin expansion in H1 FY25, but revenue growth remains weak. With 25+ stores planned, can its shift to physical retail drive long-term gains? Read more.
Pro Medicus (ASX: PME) Share Price Down On Fantastic H1 FY 2025 Results
The Pro Medicus (ASX: PME) share price was down slightly in response to the very strong Pro Medicus H1 FY 2025 results.
Prophecy International (ASX: PRO) Touts Itself As “AI Enabler” In “Business Growth Update” Disclosing 1% Revenue Growth
AI and cybersecurity are so hot right now yet this little loss making ASX software stock languishes.
Northern Star (ASX:NST) Half-Year Results: Riding the Gold Wave
Northern Star benefitted from higher gold prices, but free cashflow is restrained by capex requirements.
Bravura Solutions (ASX: BVS) Share Price Up On Increased Guidance And Solid H1 FY 2025 Results
The Bravura Solutions (ASX: BVS) turnaround is complete, and the Bravura share price is up 18% after the H1 FY 2025 results.
CAR Group (ASX: CAR) and REA Group (ASX: REA) FY 2024 Results At A Glance
Two of the most beautiful business models on the ASX. REA Group (ASX: REA) and CAR Group (ASX: CAR) may not be cheap but they sure are quality.
An Introduction To The Environmental Group (ASX: EGL): An Environmentally Positive ASX Stock
While the EGL share price has been volatile the underlying business is growing; and it helps the environment!
Is This Hidden Gem Still Flying Under the Radar?
This stock is on track to overtake Pro Medicus to become my largest ASX portfolio position. On some days it already has!
Dropsuite (ASX: DSE) Q4 FY 2024 Quarterly Results Analysis
Although overshadowed by the takeover offer, Dropsuite’s Q4 FY2024 were surprisingly strong and pleasing.
An Introduction to Australian Finance Group Shares (ASX: AFG)
AFG shares boast a P/E ratio under 15 times, a grossed up dividend yield of over 7.4%, and potential for growth.
A Comment On The Genetic Signatures Share Price (ASX: GSS)
The Genetic Signatures (ASX: GSS) share price suffers from its lack of profitability, but the diagnostic testing company may be on the verge of substantial growth.